Inhaled bronchodilators relax constricted airways and treat the noisy part of asthma: coughing, wheezing, choking and shortness of breath.
|
|
|
- Jasmin Holmes
- 6 years ago
- Views:
Transcription
1 Inhaled bronchodilators relax constricted airways and treat the noisy part of asthma: coughing, wheezing, choking and shortness of breath. AccuNeb inhalation 0.021% solution: 0.63mg/3mL 3-4 times solution 0.042% solution: 1.25 mg/3ml Advair Diskus 100/50 250/50 500/50 Advair HFA 45/21 115/21 230/21 Alent inhalation 100mcg /50mcg 250mcg /50mcg 500mcg /50mcg 45mcg /21mcg 115mcg /21mcg 230mcg /21mcg 0.021% solution: 0.63mg/3mL 0.042% solution: 1.25 mg/3ml 0.083% solution: 2.5mg/3mL. 5% solution: 2.5mg/0.5mL metaproterenol sulfate 3-4 times 65 mcg per inhalation 3-4 times 2 yrs & Dey L.P. 4 yrs & 2 yrs & 2 yrs & 2 yrs & GlaxoSmithKline Note: Advair does not replace fast-acting s for sudden symptoms and should not be taken more than twice a day. Advair HFA now has an integrated dose counter various manufacturers DISCONTINUED Charts Updated August 18, 2010 Copyright 2010 All Rights Reserved Page 1
2 Inhaled bronchodilators (continued) Atrovent HFA inhalation Brovana Combivent Dulera DuoNeb inhalation solution Foradil! Aerolizer ipratropium bromide HFA ar tartrate ipratroprium bromide and mometasone furoate and ipratroprium bromide and 21 mcg per inhalation 4 times 2 ml/2.1ml 18 mcg ipratropium bromide/ 103 mcg per inhalation 100 mcg mometasone/5 mcg 200 mcg mometasone/5 mcg 0.5mg ipratropium/3mg albuterol in 3mL unit dose vials 4 times 4-6 times 12 mcg per inhalation Note: Atrovent is not indicated for the initial treatment of acute episodes of bronchospasm where rapid response is required. Sepracor Note: Brovana is not indicated to relieve acute respiratory symptoms Merck Inc. Dey 5 yrs & Schering Corp. Note: Foradil is not indicated to relieve acute asthma symptoms. Charts Updated August 18, 2010 Copyright 2010 All Rights Reserved Page 2
3 Inhaled Bronchodilators (continued) ipratroprium bromide ipratropium bromide and Maxair" Autohaler metaproterenol sulfate Perforomist ipratroprium bromide ipratropium bromide and pirbuterol acetate metaproterenol sulfate breath-actuated ProAir HFA HFA Proventil! HFA Serevent! Diskus! xinafoate 0.02% solution: 0.5mg/2.5mL 0.5mg ipratropium/3mg albuterol in 3mL unit-dose vials 3-4 times 4-6 times 200 mcg per inhalation 3-4 times 0.4% solution: 10mg/2.5mL 0.6% solution: 15mg/2.5mL 3-4 times 20mcg/2mL 90 mcg per inhalation 3-4 times 108 mcg per inhalation 3-4 times 50 mcg per inhalation various various manufacturers 3M Pharmaceuticals various manufacturers Dey Note: Perforomist is not indicated to treat asthma or acute deteriorations of COPD 4 yrs & TEVA Respiratory 4 yrs & Schering Corp. 4 yrs & GlaxoSmithKline Note: Serevent should not be used to relieve acute asthma symptoms Charts Updated August 18, 2010 Copyright 2010 All Rights Reserved Page 3
4 Inhaled bronchodilators (continued) Spiriva HandiHaler Symbicort inhalation 80/ /4.5 tiotropium bromide budesonide and Ventolin HFA Xopenex inhalation solution Xopenex inhalation solution concentrate Xopenex HFA levalbuterol HCI levalbuterol tartrate 18 mcg per inhalation 1 time per day 80mcg budesonide/4.5mcg per inhalation 160mcg budesonide/4.5mcg per inhalation 108 mcg per inhalation 3-4 times 0.31mg/3mL unit-dose vial 0.63mg/3mL unit-dose vial 1.25mg/3mL 1.25mg/0.5mL 3 times 45 mcg per inhalation 3-4 times 12 yrs and Note: Spiriva is not indicated for the initial treatment of acute episodes of bronchospasm. AstraZeneca Note: Symbicort is not indicated for the relief of acute bronchospasm. manufacturers Symbicort (HFA) now has an integrated dose counter 4 yrs & GlaxoSmithKline Note: Ventolin HFA now has an integrated dose counter 6 yrs & 4 yrs & Sepracor Inc. Charts Updated August 18, 2010 Copyright 2010 All Rights Reserved Page 4
5 Inhaled corticosteroids and other anti-inflammatory medications reduce and prevent airway inflammation (swelling). Used daily, anti-inflammatories treat the underlying part of asthma patients may not feel. Advair Diskus 100/50 250/50 500/50 Advair HFA 45/21 115/21 230/21 AeroBid AeroBid -M (menthol) flunisolide Aerospan HFA flunisolide Alvesco HFA 80 mcg 160 mcg Asmanex Twisthaler 110 mcg 220 mcg Azmacort inhalation ciclesonide mometasone furoate triamcinolone acetonide 100mcg /50mcg 250mcg /50mcg 500mcg /50mcg 45mcg /21mcg 115mcg /21mcg 230mcg /21mcg 250 mcg per inhalation 80 mcg per inhalation 80 mcg per inhalation 160 mcg per inhalation mcg per inhalation 220 mcg per inhalation 100 mcg per inhalation 2-4 times 4 yrs & Charts Updated August 18, 2010 Copyright 2010 All Rights Reserved Page 5 GlaxoSmithKline Note: Advair does not replace fast-acting s for sudden symptoms and should not be taken more than twice a day. Advair HFA now has an integrated dose counter 6 yrs & Forest Pharmaceuticals Inc. 6 yrs & Acton Pharmaceuticals NOT YET AVAILABLE Sepracor Inc. 4 yrs & Schering Corp. 6 yrs & Kos Pharmaceuticals DISCONTINUED
6 Inhaled corticosteroids and other anti-inflammatories (continued) cromolyn sodium Dulera Flovent Diskus 50 mcg 100 mcg 250 mcg Flovent HFA 44 mcg 110 mcg 220 mcg Intal Inhaler cromolyn sodium mometasone furoate and formoerol propionate cromolyn sodium 10mg/mL 4 times 100 mcg mometasone/5 mcg 200 mcg mometasone/5 mcg 50 mcg per inhalation 100 mcg per inhalation 250 mcg per inhalation 44 mcg per inhalation 110 mcg per inhalation 220 mcg per inhalation 800 mcg per inhalation 4 times Pulmicort Respules budesonide 0.25mg/2mL unit-dose ampule 0.5mg/2mL unit-dose ampule 1mg/2mL unit-dose ampule Pulmicort Flexhaler 90 mcg per inhalation 90 mcg 180 mcg per inhalation 180 mcg QVAR 40 mcg 80 mcg Symbicort inhalation 80/ /4.5 beclomethasone dipropionate HFA budesonide and 40 mcg per inhalation 80 mcg per inhalation 80mcg budesonide/4.5mcg per inhalation 160mcg budesonide/4.5mcg per inhalation 1- a day 2 yrs & various manufacturers Merck Inc. Note: Dulera has an integrated dose counter 4 yrs & GlaxoSmithKline Note: Flovent HFA now has an integrated dose counter 5 & King Pharmaceuticals DISCONTINUED 12 months 8 yrs 6 yrs & AstraZeneca LP 5 yrs & Teva Specialty Pharmaceuticals LLC AstraZeneca Note: Symbicort is not indicated for the relief of acute bronchospasm. Charts Updated August 18, 2010 Copyright 2010 All Rights Reserved Page 6
7 Leukotriene Modifiers Accolate zafirlukast tablets 10 mg tablets 20 mg tablets Singulair montelukast tablets 4 mg chewable tablets 1 time per sodium 5 mg chewable tablets day 10 mg coated tablets granules 4 mg packets Zyflo zileuton tablets 600 mg tablets 4 times Zyflo CR extended release tablets 5 yrs & AstraZeneca 12 mos & Merck & Co. Inc. Cornerstone Therapeutics Charts Updated August 18, 2010 Copyright 2010 All Rights Reserved Page 7
First to Market or 505 (b)2 CMC Considerations IPAC-RS/UF Orlando Inhalation Conference Orlando, Florida
First to Market or 505 (b)2 CMC Considerations IPAC-RS/UF Orlando Inhalation Conference Orlando, Florida Prasad Peri, Ph.D., Branch Chief, ONDQA, FDA March 19, 2014 1 Topics for discussion Introduction
Diagnosis and Management of Asthma
Supporting Evidence: Diagnosis and Management of Asthma The subdivision of this section is: Appendix B Tables Copyright 2016 by 1 Eleventh Edition/December 2016 Appendix B Asthma Summary Tables Class:
Foundations of Pharmacology
Pharmacologic Management of Asthma Objectives: 1. Review the physiological basis for asthma therapy 2. Discuss the differences between SABA and LABA 3. Discuss the role of inhaled and oral systemic corticosteroids
Select Inhaled Respiratory Agents
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
Asthma medications: Know your options - MayoClinic.com. Asthma medications: Know your options
MayoClinic.com reprints This single copy is for your personal, noncommercial use only. For permission to reprint multiple copies or to order presentation-ready copies for distribution, use the reprints
A Visual Approach to Simplifying Respiratory Drug Regimens
A Visual Approach to Simplifying Respiratory Drug Regimens Stephanie Cheng, PharmD, MPH, BCGP 3 Main Categories Inhaled Respiratory Drugs Binds to beta-2 receptors Relaxation of smooth muscles in the lung
A Visual Approach to Simplifying Respiratory Drug Regimens
A Visual Approach to Simplifying Respiratory Drug Regimens Stephanie Cheng, PharmD, MPH, BCGP October 23, 2017 Learning Objectives Be able to list at least 3 major adverse effects of inhaled medications
A Visual Approach to Simplifying Respiratory Drug Regimens
Adverse Effects of Inhaled Medications A Visual Approach to Simplifying Respiratory Drug Regimens Stephanie Cheng, PharmD, MPH, BCGP June 28, 2017 Drug Category Beta 2 agonists antagonists Adverse Effects
Asthma. Definition. Symptoms
Asthma Definition Asthma is a condition in which your airways narrow and swell and produce extra mucus. This can make breathing difficult and trigger coughing, wheezing and shortness of breath. For some
Inhaled Corticosteroid Dose Comparison in Asthma
This Clinical Resource gives subscribers additional insight related to the Recommendations published in April 2017 ~ Resource #330402 Inhaled Corticosteroid Dose Comparison in Asthma The chart below provides
II: Moderate Worsening airflow limitations Dyspnea on exertion, cough, and sputum production; patient usually seeks medical
Table 3.1. Classification of COPD Severity Stage Pulmonary Function Test Findings Symptoms I: Mild Mild airflow limitations +/ Chronic cough and sputum production; patient unaware of abnormal FEV 1 80%
End Stage COPD Guidance Document
End Stage COPD Guidance Document Suggested Guidelines for the Determination of Hospice Eligibility A patient with severe chronic pulmonary disease that meets the following criteria may be eligible for
Ferris State University College of Pharmacy MPA CE Symposium 2016 Paul Thill, PharmD, BCPS
Ferris State University College of Pharmacy MPA CE Symposium 2016 Paul Thill, PharmD, BCPS Objectives Categorize the new asthma and COPD inhalers in to existing or newly created categories Discuss the
TRELEGY ELLIPTA (fluticasone-umeclidinium-vilanterol) aerosol powder
TRELEGY ELLIPTA (fluticasone-umeclidinium-vilanterol) aerosol powder Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific
Respiratory Medications and Devices Update 2/15
Respiratory Medications and Devices Update 2/15 Dewey Hahlbohm, PA-C, AE-C Wendy Brown, Pharm.D., MPAS, PA-C, AE-C Objectives! Review mechanism of action for asthma pharmacologic agents! Describe key patient
Medications Affecting The Respiratory System
Medications Affecting The Respiratory System Overview Asthma is a chronic inflammatory disorder of the airways. It is an intermittent and reversible airflow obstruction that affects the bronchioles. The
FASENRA (benralizumab)
FASENRA (benralizumab) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
AIRDUO RESPICLICK (fluticasone-salmeterol) aerosol DULERA (mometasone furoate and formoterol fumarate dihydrate) aerosol
DULERA (mometasone furoate and formoterol fumarate dihydrate) aerosol Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific
Staying Healthy. with Asthma. Illustrations by paulsharp.com
Staying Healthy with Asthma Illustrations by paulsharp.com Lungs & Asthma What is Asthma? Inflammation or swelling of airways that leads to: 1) Mucous production deep inside the airways. 2) Temporary difficulty
MEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 07/05/18 SECTION: DRUGS LAST REVIEW DATE: LAST CRITERIA REVISION DATE: ARCHIVE DATE:
CINQAIR (reslizumab) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
MANAGING ASTHMA. Nancy Davis, RRT, AE-C
MANAGING ASTHMA Nancy Davis, RRT, AE-C What is asthma? Asthma is a chronic respiratory disease characterized by episodes or attacks of inflammation and narrowing of small airways in response to asthma
Using Inhaled Corticosteroids as Needed for Asthma: giving patients relief or leaving them breathless?
Using Inhaled Corticosteroids as Needed for Asthma: giving patients relief or leaving them breathless? Lindsay Thomas, Pharm.D. PGY2 Ambulatory Care Resident Department of Pharmacotherapy and Pharmacy
Nancy Davis, RRT, AE-C
Nancy Davis, RRT, AE-C Asthma Statistics 25.6 million Americans diagnosed with asthma 6.8 million are children 10.5 million missed school days per year 14.2 lost work days for adults Approximately 10%
COPD Medicine. No one ever showed me how to use this. Wendy Happel; RRT, COPD Educator Krystal Fedoris; RRT-NPS, BA, COPD Educator
Medicine. No one ever showed me how to use this. Wendy Happel; RRT, Educator Krystal Fedoris; RRT-NPS, BA, Educator 1 Taking prescriptions correctly Taking prescriptions can be a challenge Busy schedules
Drug Class Monograph
Drug Class Monograph Class: Inhaled Corticosteroids Drugs: Aerospan (flunisolide), Advair Diskus, Advair HFA (fluticasone/salmeterol), Alvesco (ciclesonide), Arnuity Ellipta (fluticasone furoate), Asmanex
Commissioner for the Department for Medicaid Services Selections for Preferred Products
Commissioner for the Department for Medicaid Services Selections for Preferred Products This is a summary of the final Preferred Drug List (PDL) selections made by the Commissioner for the Department for
10/18/2012. Penn State University Children s Hospital JODIE STABINSKI CRNP MSN AE-C
Penn State University Children s Hospital JODIE STABINSKI CRNP MSN AE-C Daily: Long-Term Control Corticosteroids (inhaled and systemic) Long-acting beta 2 -agonists (Serevent, Foradil) Methylxanthines
Pain Oral-Intranasal Fentanyl (Abstral, Actiq, Fentora, Lazanda, Onsolis, Subsys)
Pennsylvania Employees Benefit Trust Fund (PEBTF) and n- Medicare Eligible Retired Employees Health Program (REHP), Step Therapy and Quantity Limit List Your doctor needs to get prior authorization for
Secretary for Health and Family Services Selections for Preferred Products
Secretary for Health and Family Services Selections for Preferred Products This is a summary of the final Preferred Drug List (PDL) selections made by the Secretary for Health and Family Services based
Aerospan (flunisolide)
STRENGTH DOSAGE FORM ROUTE GPID 80mcg/actuation HFA aerosol inhaler w/ Inhaled 35718 8.9 g/canister adapter MANUFACTURER Meda Pharmaceuticals INDICATION Aerospan Inhalation Aerosol is indicated for the
See Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Fasenra) Reference Number: CP.PHAR.## Effective Date: 01.16.18 Last Review Date: 05.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy
Asthma/COPD Update with Inhaler Workshop
Asthma/COPD Update with Inhaler Workshop October 8, 2017 Nathan Samsa, DO, Pharm D, RPh, FACOI None Disclosures Agenda Asthma Updates COPD Updates Inhaler Workshop Medication Acronyms SABA: Short acting
REVISED RESPIRATORY MEDICATION USE QUESTIONNAIRE
REVISED RESPIRATORY MEDICATION USE QUESTIONNAIRE ID NUMBER: 0a) Date of Collection / / 0b) Staff Code Instructions: This form should be completed during the participant s clinic visit. 1) Are you regularly
Common Inhaled Asthma Medications Dose Comparison and Tips for Use
Detail-Document #210303 This Detail-Document accompanies the related article published in PHARMACIST S LETTER / PRESCRIBER S LETTER March 2005 ~ Volume 21 ~ Number 210303 Common Inhaled Asthma Medications
12/18/2017. Disclosures. Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing
Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School
Women Beware-The Threat of COPD
Page 1 Speaker: Catherine Cooke attained her Bachelor in Pharmacy from the University of Iowa and then went on to receive her Pharm.D. from the Medical University of South Carolina. Subsequently, she completed
STRIVERDI RESPIMAT (olodaterol hcl) aerosol
STRIVERDI RESPIMAT (olodaterol hcl) aerosol Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
The Medical Letter. on Drugs and Therapeutics
The Medical Letter publications are protected by US and international copyright laws. Forwarding, copying or any other distribution of this material is strictly prohibited. For further information call:
Provider Respiratory Inservice
Provider Respiratory Inservice 2 Welcome Opening Remarks We will cover: Definition of Asthma & COPD Evidence based guidelines for diagnosis, evaluation, and management of asthma Evidence based guidelines
ANTINEOPLASTIC DRUGS CHAPTER 21. Antineoplastic drugs - designed to treat malignancies, now also used to treat diseases with inflammatory component
ANTINEOPLASTIC DRUGS CHAPTER 21 Antineoplastic drugs - designed to treat malignancies, now also used to treat diseases with inflammatory component Tx of malignancies Antineoplastic drugs: methotrexate
Methacholine Challenge Test
PATIENT & CAREGIVER EDUCATION Methacholine Challenge Test This information will help you prepare for your methacholine challeng e test at Memorial Sloan Kettering (MSK). A methacholine (meth-a-kole-leen)
reslizumab (Cinqair )
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
Reference Guide for Caring for Pediatric Patients with Asthma
Reference Guide for Caring for Pediatric Patients with Asthma Co-Chair: Nancy Cantey Banasiak, DNP, PPCNP-BC, APRN Co-Chair: Deborah Hickman, DNP, APRN-CNP, CPNP-PC, NNP-BC Asthma and Allergy SIG Members
Breath of Fresh Air. nniversary 20th. New National Asthma Survey: How Does Your Asthma Compare? Long-Acting Bronchodilators: Why All the Fuss?
Information, news and advice for improving asthma well-being Volume 12, No. 1 Summer 2010 New National Asthma Survey: How Does Your Asthma Compare? nniversary 20th Sometimes if one has to live with a chronic
Asthma By Mayo Clinic staff
MayoClinic.com reprints This single copy is for your personal, noncommercial use only. For permission to reprint multiple copies or to order presentation-ready copies for distribution, use the reprints
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Asthma/COPD P&T DATE 12/14/2017 CLASS:
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Asthma/COPD P&T DATE 12/14/2017 CLASS: LOB: Respiratory Disorders Medi-Cal REVIEW HISTORY (MONTH/YEAR) 12/17,12/16, 5/15,
Women Beware The Threat of COPD
Page 1 Women Beware The Threat of COPD Catherine E. Cooke, PharmD, BCPS, PAHM President, PosiHealth, Inc. & Clinical Associate Professor, University of Maryland School of Pharmacy Supported by an education
Correct Use of Inhaler Devices
PL Detail-Document #300206 This PL Detail-Document gives subscribers additional insight related to the Recommendations published in PHARMACIST S LETTER / PRESCRIBER S LETTER February 2014 Correct Use of
Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing
Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School
Proposed Preferred Drug List. Clinical Criteria
Proposed Preferred Drug List with Clinical Criteria Proposal for TennCare February 7, 2008 Page 1 of 87 PDL Decision Process The primary clinical decision that needs to be made is determining if the drugs
Learning Objectives 4/26/2012. Review normal lung function and COPD pathophysiology Discuss pharmacological management
Marliese Gibson PharmD HospiScript, a Catalyst Rx Company May 16, 2012 Chronic Obstructive Pulmonary Disease Learning Objectives Review normal lung function and COPD pathophysiology Discuss pharmacological
Key features and changes to these four components of asthma care include:
Guidelines for the Diagnosis and Management of Asthma in Adults Clinical Practice Guideline MedStar Health These guidelines are provided to assist physicians and other clinicians in making decisions regarding
Drug Effectiveness Review Project Summary Report
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
Medications for Managing COPD in Hospice Patients. Jim Joyner, PharmD, CGP Director of Clinical Operations Outcome Resources
Medications for Managing COPD in Hospice Patients Jim Joyner, PharmD, CGP Director of Clinical Operations Outcome Resources Goal of medications in COPD Decrease symptoms and/or complications Reduce frequency
ASTHMA IN THE PEDIATRIC POPULATION
ASTHMA IN THE PEDIATRIC POPULATION SEARCH Rotation 2 August 23, 2010 Objectives Define asthma as a chronic disease Discuss the morbidity of asthma in pediatrics Discuss a few things that a health center
benralizumab (Fasenra )
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
Drug Class Review. Controller Medications for Asthma
Drug Class Review Controller Medications for Asthma Final Report November 2008 The Agency for Healthcare Research and Quality has not yet seen or approved this report. The purpose of this report is to
MDI Bonanza. Dwayne Griffin, DO
MDI Bonanza Dwayne Griffin, DO Bonanza 3. A MDI costing $200 - $500 per month SISYPHUS MDI Griffin Mountain Evolution of Deliver Systems for COPD in the US 2003 2009 2011 2013 2004 2012 2014 Prescribing
Inhaled Corticosteroids Drug Class Prior Authorization Protocol
Inhaled Corticosteroids Drug Class Prior Authorization Protocol Line of Business: Medi-Cal P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review
Drug Class Review. Controller Medications for Asthma
Drug Class Review Controller Medications for Asthma Final Update 1 Report April 2011 The Agency for Healthcare Research and Quality has not yet seen or approved this report. The purpose of this report
University System of Georgia Prior Authorization, Step Therapy and Quantity Limit List (Updated 1/1/2016)
University System of Georgia, Step Therapy and Quantity Limit List (Updated 1/1/2016) (PA) Your doctor will need to obtain a prior authorization for the drugs listed below, before your prescription drug
Inhaled Corticosteroids Drug Class Prior Authorization Protocol
Inhaled Corticosteroids Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review
Q: Should patients with mild asthma
1-MINUTE CONSULT CME CREDIT EDUCATIONAL OBJECTIVE: Readers will consider prescribing inhaled corticosteroids to their patients who have mild persistent asthma brief answers to specific clinical questions
Asthma in Pregnancy. Asthma. Chronic Airway Inflammation. Objective Measures of Airflow. Peak exp. flow rate (PEFR)
Chronic Airway Inflammation Asthma in Pregnancy Robin Field, MD Maternal Fetal Medicine Kaiser Permanente San Francisco Asthma Chronic airway inflammation increased airway responsiveness to a variety of
Asthma. Introduc:on. Introduc:on. Anatomic Altera:ons of the Lungs. Introduc:on. RSPT 2310 Asthma RSPT 2310
DMC = Degranula:on of mast cell MA = Mucus accumula:on HALV = Hyperinfla:on of alveoli MP = Mucus plug SMC = Smooth muscle constric:on RSPT 2310 Introduc:on The first evidence based asthma guidelines were
agonist in patients 6 years and older with reversible airway disease and acute attacks of bronchospasm
Pharmaceutical Listing 2009 Buyers Guide This listing, organized by indication, is a quick way to find commonly used respiratory and sleep drugs. Consult the manufacturer s full prescribing information
Relative Cost/Month. Less than $10. Loratadine Liquid* $10-$15 Cetirizine liquid 1mg/mL*
Allergy Chlorpheniramine Tablet* Diphenhydramine Tablet* Diphenhydramine Liquid* Loratadine Tablet* Cetirizine Tablet* Loratadine 10mg ODT* Less than $10 Loratadine Liquid* $10-$15 Cetirizine liquid 1mg/mL*
CAMPER APPLICATION PACKET
CAMPER APPLICATION PACKET Monday- Friday June 12-16, 2017 Rockport, Texas DEADLINE FOR SUBMITTING ALL FORMS: THE IMPORTANCE OF COMPLETING ALL CAMP FORMS Although it may seem like a lot of paperwork, the
Pequot Health Care Smart Quantity Program*
Pequot Health Care 1 Annie George Drive Mashantucket, CT 06338 Phone: 1-888-779-6638 Fax: 1-860-396-6494 Pequot Health Care Smart Quantity Program* Updated January 2018 *Quantity Program limits apply to
Drugs that Affect the Respiratory System BROOKE BENTLEY, PHD, APRN
Drugs that Affect the Respiratory System BROOKE BENTLEY, PHD, APRN Goals of Therapy Asthma Prevent symptoms COPD Reduce COPD symptoms Decrease use of SABAs Maintain normal pulm function & prevent loss
4/3/2018 BRANDY BURGESS, APRN-CNS, MSN-RN APRIL 12-14, 2018
BRANDY BURGESS, APRN-CNS, MSN-RN APRIL 12-14, 2018 Approach to treatment List of medication Abbreviations When to use medications Pharmokinetics Pharmacodynamics Step wise therapy both for acute and chronic
A Patient s Guide to Aerosol Medication Delivery
A Patient s Guide to Aerosol Medication Delivery 3rd Edition Prepared by: Tim Op t Holt, EdD, RRT, AE-C, FAARC Kimberly Wiles, RRT, CPFT Ellen Becker, PhD, RRT, RRT-NPS, RPFT, AE-C, FAARC Edited by: Timothy
Pharmacy Medical Policy Asthma and Chronic Obstructive Pulmonary Disease Medication Management
Pharmacy Medical Policy Asthma and Chronic Obstructive Pulmonary Disease Medication Management Table of Contents Policy: Commercial Information Pertaining to All Policies Endnotes Policy: Medicare References
Impact of a Comprehensive COPD Therapeutic Interchange Program on 30-Day Readmission Rates in Hospitalized Patients
Impact of a Comprehensive COPD Therapeutic Interchange Program on 30-Day Readmission Rates in Hospitalized Patients Maren A. McGurran, PharmD, BCPS; Lisa M. Richter, PharmD, BCPS, BCCCP; Nathan D. Leedahl,
Oregon Health Plan prescription benefit updates
Oregon Health Plan prescription benefit updates EOCCO s prescription program is a pharmacy benefit that offers members a choice of safe and effective medication treatments. The program also helps you save
Allergies and Asthma 5/21/2013. Objectives. Allergic Rhinitis (AR): Risk Factor for ASTHMA. Rhinitis and Asthma
Allergies and Asthma Presented By: Dr. Fadwa Gillanders, Pharm.D Clinical Pharmacy Specialist May 2013 Objectives Understand the relationship between asthma and allergic rhinitis Understand what is going
Clinical Policy: Omalizumab (Xolair) Reference Number: ERX.SPA.141 Effective Date: Last Review Date: 08.17
Clinical Policy: (Xolair) Reference Number: ERX.SPA.141 Effective Date: 03.01.14 Last Review Date: 08.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
Data Class: Internal. 1 inhaler (30 blisters OR 14 blisters institutional pack) per presciption
To help make the use of prescription drugs safer and more affordable, our plan is now using a Drug Quantity Management program. That is, for certain medications, you can receive an amount to last you a
See Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Nucala) Reference Number: CP.PHAR.200 Effective Date: 04.01.16 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Coding Implications Revision Log See Important Reminder at
September 2009 Based on Data collected for the DERP report of 11/2008
Controller Medications for Asthma September 2009 Based on Data collected for the DERP report of 11/2008 Produced by: The Health Resources Commission Office for Oregon Health Policy & Research 1225 Ferry
Asthma. doh.sd.gov/statistics/2009brfss/asthma.pdf
is an obstructive or restrictive condition which inhibits airflow due to inflammation of the airway. This obstruction occurs via increased edema in the small bronchioles walls as well as greater production
Question I was one of the first dry power devices available in the US Flovent, Serevent and Advair are all available in this device
What Device am I Class Side Effects History Potpourri Monitoring Tools 10 10 10 10 10 20 20 20 20 20 30 30 30 30 30 40 40 40 40 40 50 50 50 50 50 WHAT KIND OF DEVICE AM I? I was one of the first dry power
Respiratory Health. Asthma and COPD
Respiratory Health Asthma and COPD Definition of asthma Working definition by AAH 2014: Chronic lung disease Can be controlled not cured Large variation in lung function Large variation in respiratory
APPENDIX 1 Printable point-of-care tables Asthma Action Plan Yellow Zone Formulation Table Region: Europe
APPENDIX 1 Printable point-of-care tables Asthma Action Plan Yellow Zone Formulation Table Region: Europe Instructions: Print on 8.5 x14 (216 x 279 mm) paper (Legal size) Medication in Green Zone Change
Cinqair (reslizumab injection for intravenous use)
Cinqair (reslizumab injection for intravenous use) Policy Number: 5.02.522 Last Review: 04/2018 Origination: 04/2016 Next Review: 04/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will
Taking Control of Asthma Through Proper Medication Selection and the Use of Asthma Action Plans Julie M. Koehler, Pharm.D., FCCP
Taking Control of Asthma Through Proper Medication Selection and the Use of Asthma Action Plans Julie M. Koehler, Pharm.D., FCCP Associate Dean for Clinical Education and External Affiliations & Professor
How to Manage Asthma
How to Manage Asthma Table of Contents I. What is Asthma? Page 2 II. How Do Your Lungs Work Page 2 III. What Triggers an Asthma Attack? Page 3 IV. How to Control Asthma Triggers Page 3 V. Your Peak Flow
CLINICAL MEDICAL POLICY
CLINICAL MEDICAL POLICY Policy Name: Xolair (omalizumab) Policy Number: MP-051-MD-DE Responsible Department(s): Medical Management; Clinical Pharmacy Provider Notice Date: 10/01/2017 Original Effective
9/14/12. Nicole Paterson, PharmD BCPS Medication Therapy Management Provider Fairview Pharmacy Services, LLC
Nicole Paterson, PharmD BCPS Medication Therapy Management Provider Fairview Pharmacy Services, LLC } Describe the pathophysiology of asthma and Chronic Obstructive Pulmonary Disease (COPD). } Review the
Asthma Pharmacotherapy 2017: Stepwise Approach to Managing Asthma
Asthma Pharmacotherapy 2017: Stepwise Approach to Managing Asthma Webinar for Michigan Center for Clinical Systems Improvement (Mi-CCSI) Karen Meyerson, MSN, APRN, NP-C, AE-C Director, Commercial Care
Nucala (mepolizumab injection for subcutaneous use)
Nucala (mepolizumab injection for subcutaneous use) Policy Number: 5.01.612 Last Review: 01/2018 Origination: 02/2016 Next Review: 02/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will
QUANTITY LIMIT CRITERIA. BROVANA (arformoterol tartrate) SEREVENT DISKUS (salmeterol) STRIVERDI RESPIMAT (olodaterol)
Carelirst. +.V Family of health care plans DRUG CLASS COMBINATIONS QUANTITY LIMIT CRITERIA LONG ACTING BETA2-ADRENERGIC AGONIST, ORAL INHALATION BRAND NAME (generic) LONG-ACTING BETA2-ADRENERGIC AGONISTS:
Asthma & COPD Medication Review. Hutchison Disclosures 2/16/2017. Objectives
Asthma & COPD Medication Review Anna Meador, PharmD, BCACP Assistant Professor/ Pharmacy Director McWhorter School of Pharmacy/ Christ Health Center Amber Hutchison, PharmD, BCPS Assistant Clinical Professor
Bronchiectasis. Examples include: Viral infections (measles, adenovirus, influenza)
Bronchiectasis What is Bronchiectasis? Bronchiectasis (pronounced bron-kee-ek'-tas-is) is a condition of the airways in the lungs. These airways (bronchial tubes) are tubelike structures that branch from
Improving Outcomes in COPD
Neil MacIntyre MD Duke University Durham NC Current treatment guidelines f COPD focus Barriers to providing optimal treatment Diagnosis of COPD EXPOSURE TO RISK FACTORS AND/ OR SYMPTOMS sputum cough dyspnea
Clinical Policy: Dupilumab (Dupixent) Reference Number: ERX.SPA.49 Effective Date:
Clinical Policy: (Dupixent) Reference Number: ERX.SPA.49 Effective Date: 06.01.17 Last Review Date: 02.19 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
Breath of Fresh Air. Information, news and advice for improving asthma well-being. National Asthma Guidelines: A Stepped Approach to Asthma Therapy
Information, news and advice for improving asthma well-being Volume 11, No. 1 Summer 2008 National Asthma Guidelines: A ped Approach to Asthma Therapy In the last issue of Breath of Fresh Air, we discussed
See Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Seebri Neohaler) Reference Number: CP.CPA.150 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy
DOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL
DOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL I. Uniform Formulary Review Process Under 10 U.S.C. 1074g, as implemented by 32
2014 Quantity Limits (QL) Criteria
2014 Quantity Limits (QL) Criteria Certain drugs covered through your EmblemHealth Medicare HMO/PPO Medicare Plan are covered for only a limited quantity. We do this to ensure compliance with the US Food